SAUTÈS-FRIDMAN , Catherine

Last name: SAUTÈS-FRIDMAN

First name: Catherine

April 8, 2022 (v1)

Publication

Metadata-only

Abstract 2578: High regulatory T cells infiltrate within tertiary lymphoid structure restricts response to immune checkpoint blockers in sarcomas

Peyraud, Florent Guegan, Jean-Philippe Rey, Christophe

Abstract Background: While composition of the tumor microenvironment (TME) is a prerequisite for an effective antitumor immunity, infiltration of organized B- and T-cells aggregates called tertiary lymphoid structures (TLS) has been recently demonstrated to predict response to immune checkpoint blockers (ICB) in sarcomas. However, only a...

Uploaded on: September 12, 2024
May 2022 (v1)

Journal article

Metadata-only

Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial

Vano, Yann-Alexandre Elaidi, Réza Bennamoun, Mostefa

No description

Uploaded on: October 16, 2023
May 2022 (v1)

Journal article

Metadata-only

Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial

Vano, Yann-Alexandre Elaidi, Réza Bennamoun, Mostefa

Background: We previously reported a 35-gene expression classifier identifying four clear-cell renal cell carcinoma groups (ccrcc1 to ccrcc4) with different tumour microenvironments and sensitivities to sunitinib in metastatic clear-cell renal cell carcinoma. Efficacy profiles might differ with nivolumab and nivolumab-ipilimumab. We therefore...

Uploaded on: April 20, 2023

SAUTÈS-FRIDMAN , Catherine

Recent uploads